Department of Biomedicine🔬🧪
LightNews LightNews
banner
biomedizin.unibas.ch
Department of Biomedicine🔬🧪
@biomedizin.unibas.ch
200 followers 59 following 34 posts
As a joint venture of the University of Basel and the University Hospitals Basel, the Department of Biomedicine (DBM) brings together basic and clinical scientists to advance our understanding of health and disease.
Posts Replies Media Videos
Pinned
biomedizin.unibas.ch
Department of Biomedicine🔬🧪 @biomedizin.unibas.ch · Feb 4
🔬 Meet the people behind the discoveries! Want to connect? Explore their latest research and insights and connect with our researchers on Bluesky.

go.bsky.app/3jJYova

#MeetOurResearchers #DBM #DepartmentofBiomedicine
biomedizin.unibas.ch
New from the @momobentires.bsky.social Lab: dexamethasone shows promise in advanced ER+/HER2– breast cancer. Led by Madhuri Manivannan, the team found that activating the GR can shut down ER signaling, curb liver mets & boost survival—esp. in ESR1-mutant disease.
👉 www.embopress.org/doi/full/10....
Activated glucocorticoid receptor is an estrogen receptor silencer in ER+ metastatic breast cancer | EMBO Molecular Medicine
imageimageThe crosstalk between steroid nuclear receptors in ER positive breast cancer largely impinges on disease progression to metastasis and therapy resistance. This study uncovers a critical effe...
www.embopress.org
November 25, 2025 at 8:23 AM
biomedizin.unibas.ch
Scientists from @biomedizin.unibas.ch , @embl.org and Mainz found self-sustaining inflammatory circuits in the bone-marrow niche that precede blood cancers, showing how inflammation rewires the microenvironment long before leukemia. Congrats to @kprummel.bsky.social et al. 🧪 doi.org/10.1038/s414...
Inflammatory stromal and T cells mediate human bone marrow niche remodeling in clonal hematopoiesis and myelodysplasia - Nature Communications
Clonal haematopoiesis of indeterminate potential is driven by somatic mutations in hematopoietic stem/progenitor cells and may progress to myelodysplastic syndromes (MDS). Here authors show that the t...
doi.org
November 20, 2025 at 1:32 PM
biomedizin.unibas.ch
Our Tissue Engineering Lab has built the most advanced human bone marrow model! It supports blood cell formation, reduces the need for animal testing, and could one day aid drug testing and personalized cancer treatments.

👉 www.cell.com/cell-stem-ce...

#TissueEngeneering #HumanBoneMarrowModel
Scanning electron microscopy image of the engineered 3D bone marrow tissue colonized with human blood cells (red). (Image: Andrés García García, University of Basel, Department of Biomedicine).
November 18, 2025 at 4:54 PM
biomedizin.unibas.ch
New multicenter study from the RC2NB including members of the DBM shows granulocyte & astrocyte markers in CSF can clearly distinguish MOGAD and NMOSD from MS.

👉🏻 doi.org/10.1093/brai...

#Neuroimmunology #MOGAD #NMOSD #MS #Biomarkers
Dynamic neural pathway simulation with flashing white patches highlighting demyelination (Image Adobe Stock).
October 24, 2025 at 6:37 AM
biomedizin.unibas.ch
New findings in Science Translational Medicine reveal distinct immune signatures in MOGAD, distinguishing it from MS and pointing toward disease-specific therapies. Kudos to all involved.

👉🏻 www.science.org/doi/10.1126/...
#MOGAD #Neuroinflammation #MSResearch
Visual representation of neuroinflammation: red, reactive immune activity disrupting the normal blue neural network. The image symbolizes the immune dysregulation underlying MOG antibody–associated disease (MOGAD). Image Adobe Stock.
October 22, 2025 at 10:22 AM
biomedizin.unibas.ch
Immune clues in tumors and blood predict who benefits from neoadjuvant chemoimmunotherapy in lung cancer. Congrats to the Zippelius Lab! www.nature.com/articles/s41...

@nature.com #LungCancer #Immunotherapy #CancerResearch #Oncology #PrecisionMedicine
Microscopy images showing three separate areas of a lung tumor, representing different immune environments: desert, excluded, and inflamed. These are general examples used to illustrate how immune cells interact with tumors. The top row displays a CD8 immunohistochemistry image, while the bottom row shows a marked version where CD8+ T cells are highlighted in red and tumor cells in blue. Adopted from Schmid, D., et al. (2025), Nature Communications.
October 21, 2025 at 11:01 AM
biomedizin.unibas.ch
🚀 Breakthrough in #ProstateCancer research from @biomedizin.unibas.ch published in
@cp-cellreports.bsky.social! Matrigel-free PDOs preserve patient-specific cell populations. New single-cell atlas (PPScA) maps heterogeneity + reveals pathways altered in vitro.
Fluorescent microscopy image of antibody-labeled patient-derived organoids (PDOs), captured at Le Magnen Lab.
October 1, 2025 at 11:54 AM
biomedizin.unibas.ch
✨ Good news! The eleventh issue of our DBM newsletter is out! We hope you enjoy it! 👇🏼👇🏼👇🏼
issuu.com/departementb...

#Newsletter #Research #Science #Biomedicine #TeamDBM
Newsletter Issue 11
issuu.com
September 29, 2025 at 11:37 AM
biomedizin.unibas.ch
Researchers @biomedizin.unibas.ch developed cartilage implants from nasal septum cells, and showed that allowing them to mature for two weeks improved outcomes. 🔬Congratulations to all contributors.
doi.org/10.1126/scit...

#Immunotherapy #CancerImmunology #FusionProtein #PD1IL2v #TCellTherapy
© Martin Oeggerli (www.Micronaut.ch) 2019-2025, with Marcel Philipp Trefny, and Prof. Alfred Zippelius, Cancer Immunology, University Hospital Basel, Pathology University Hospital Basel, and C-CINA, Biozentrum, University Basel
September 18, 2025 at 7:30 AM
biomedizin.unibas.ch
New in Haematologica: Researchers at binderlab.bsky.social report a mutation-specific immunotherapy for high-risk CLL. A bispecific antibody (BiTE) redirects T cells to target IGLV3-21^R110+ leukemia cells—killing malignant cells while sparing healthy B cells.
Link: doi.org/10.3324/haem...
Bispecific antibodies as a potential off-the-shelf immunotherapy for high-risk CLL patients (Image Adobe Stock)
September 12, 2025 at 6:09 AM
biomedizin.unibas.ch
Four DBM researchers at the University of Basel just secured ERC Starting Grants!🎉

A huge congratulations to Jean-Christophe Beltra, Mariana Borsa @nanaborsa.bsky.social , Magdalena Sznurkowska & Tobias Weiss.

🔗 Full news:
biomedizin.unibas.ch/en/communica...

@erc.europa.eu #ERCStG
September 4, 2025 at 10:14 AM
biomedizin.unibas.ch
🚀 Welcome Prof. Dr. Marc Aurel Busche @marcaurelbusche.bsky.social to the DBM, University of Basel!

He’ll head the Brain Ageing & Neurodegeneration Lab, focusing on Alzheimer’s and brain circuit dysfunction. Read more: 🔗 biomedizin.unibas.ch/en/newsdetai...
September 2, 2025 at 6:51 AM
biomedizin.unibas.ch
🎊Cheers to 25 Years of Discovery @biomedizin.unibas.ch !
Since 2000, we’ve grown into one of Switzerland’s top translational research hubs — thanks to our brilliant teams & community.
We celebrated with music, laughter, science & soul. Here’s to the next 25.💙
biomedizin.unibas.ch/en/newsdetai...
August 25, 2025 at 10:37 AM
biomedizin.unibas.ch
🏆 Dr. Laurentz Schuhknecht @zampierilab.bsky.social wins DBM Research Prize; Johanna Nimmerfroh (Läubli Lab) earns 1st Best Presentation Award at our Summer Symposium. Congratulations! 🎉

biomedizin.unibas.ch/en/communica...

#DBMPrize #BestPresentationAward #ResearchExcellence
August 21, 2025 at 7:18 AM
biomedizin.unibas.ch
The 2025 DBM Summer Symposium is happening today! There will be a keynote by Prof. Mustafa Khammash @eth-bsse.bsky.social , 17 short talks, and the presentation of the DBM Research Prize 2024 and the Best Presentation Award 2025. 🧬🏆
Big thanks to all involved!
#DBMSymposium2025 #Science #TeamDBM
August 20, 2025 at 8:59 AM
biomedizin.unibas.ch
Congrats to Mascha Binder & her team @binderlab.bsky.social‬ on their new paper showing that blood-based inflammation markers-like IL-6 & cfDNA-are better than PD-L1 at predicting immunotherapy outcomes in head & neck cancer.A move toward smarter, tailored treatments. www.nature.com/articles/s41...
Inflammation and limited adaptive immunity predict worse outcomes on immunotherapy in head and neck cancer - npj Precision Oncology
npj Precision Oncology - Inflammation and limited adaptive immunity predict worse outcomes on immunotherapy in head and neck cancer
www.nature.com
August 12, 2025 at 6:11 AM
biomedizin.unibas.ch
🚀 We’re thrilled to welcome Prof. Dr. Valérie Hilgers (hilgerslab.bsky.social) to the DBM! She’ll head the RNA Biology & Neurogenetics Lab, investigating how RNA regulation drives brain development and function. ERC Consolidator Grant 2024 included. Read more: 🔗 biomedizin.unibas.ch/en/communica...
July 1, 2025 at 7:52 AM
biomedizin.unibas.ch
Meet our Expert Jürg Schwaller from the Childhood Leukemia Lab at the @Department of Biomedicine. Today he shares his research and vision for AML treatment strategies. Read more in our Blog with our Expert.

Blog with our Expert: biomedizin.unibas.ch/en/communica...

#AML #Leukemia #Cancerresearch
June 17, 2025 at 10:14 AM
biomedizin.unibas.ch
Big things are rising in Basel 🏗️

The new DBM building will bring researchers together under one roof, with a focus on collaboration, comfort, and climate-conscious design - a real boost for biomedical science in Switzerland.

#ScienceForTheFuture #DBM #Basel
June 6, 2025 at 9:38 AM
biomedizin.unibas.ch
The 10th Golden Edition of our DBM Newsletter is out now. 📰✨ A special printed copy was handed out at the 'Laying of the Foundation Stone Ceremony' on May 23 as a commemorative keepsake.
Check it out here 👉 issuu.com/departementb...

@biomedizin.unibas.ch #Newsletter #Research #TeamDBM
May 27, 2025 at 2:12 PM
biomedizin.unibas.ch
SUM-seq: New single-cell method by @biomedizin.unibas.ch , @embl.org , @au.dk ‬‬ and Tampere university enables large-scale analysis of gene activity & DNA accessibility across millions of cells.
Congrats Prof. Zaugg & collaborators!‬‬‬‬‬‬

🔗 www.nature.com/articles/s41...
Single-cell ultra-high-throughput multiplexed chromatin and RNA profiling reveals gene regulatory dynamics - Nature Methods
This work presents SUM-seq, an ultra-high-throughput method for co-profiling chromatin accessibility and gene expression in single nuclei across multiplexed samples, advancing the study of gene regula...
www.nature.com
May 26, 2025 at 2:20 PM
biomedizin.unibas.ch
🚧 Major milestone for the Department of Biomedicine: the foundation stone for the new DBM research building has been laid! A symbol of collaboration, innovation & sustainability, the new building is set to open in 2031.
Read more: biomedizin.unibas.ch/en/newsdetai...
#UniversityofBasel #DBM
Prof. Dr. Ivan Martin, Head of the Department of Biomedicine; Cantonal Councillor Mustafa Atici, Head of the Basel-Stadt Department of Education; Cantonal Councillor Monica Gschwind, Head of the Basel-Landschaft Department of Education, Culture and Sport; Dr. Rolf Borner, Director of Infrastructure & Operations at the University of Basel; Marc Brülhart, Head of Building Construction German-speaking Switzerland & Head of the Northwest Region Implenia; Dr. Beat Oberlin, President of the University Council of the University of Basel. (From left, photo: University of Basel, Christian Flierl)
May 23, 2025 at 3:10 PM
biomedizin.unibas.ch
🚀 Thrilled to welcome Professor Dr. Pietro Cippà to the DBM team! As the new Professor of Nephrology at the University of Basel and Head of our Nephrology Lab, he’s set to drive transformative breakthroughs in kidney repair and transplant immunology. Read more: 🔗 biomedizin.unibas.ch/en/communica...
April 1, 2025 at 12:29 PM
biomedizin.unibas.ch
New Research on LSD Microdosing & ADHD
A placebo-controlled study from @biomedizin.unibas.ch found no significant benefit of LSD microdosing for ADHD. Symptom improvements were driven by expectation rather than the drug itself. Congrats to Prof. Dr. Liechti & team! 🔗 jamanetwork.com/journals/jam...
Safety and Efficacy of Repeated Low-Dose LSD for ADHD Treatment in Adults
This double-blind, placebo-controlled randomized clinical trial determines the safety and efficacy of repeated low doses of lysergic acid diethylamide (LSD) in reducing attention-deficit/hyperactivity...
jamanetwork.com
March 31, 2025 at 8:13 AM
biomedizin.unibas.ch
Researchers @biomedizin.unibas.ch developed cartilage implants from nasal septum cells, and showed that allowing them to mature for two weeks improved clinical outcomes. Cartilage tissue engineering matters!

🔬Congratulations to all contributors.

🔗 www.science.org/doi/10.1126/...
Clinical relevance of engineered cartilage maturation in a randomized multicenter trial for articular cartilage repair
Engineered hyaline-like cartilage tissues are superior to immature cell-based grafts for the therapy of cartilage defects in the human knee.
www.science.org
March 6, 2025 at 7:38 AM